Full Text View
Tabular View
No Study Results Posted
Related Studies
Ofloxacin vs. Gentamicin as Prophylaxis Prior Transrectal Biopsy of Prostate
This study is not yet open for participant recruitment.
Verified by HaEmek Medical Center, Israel, May 2007
First Received: May 29, 2007   No Changes Posted
Sponsor: HaEmek Medical Center, Israel
Information provided by: HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier: NCT00480376
  Purpose

Prostate biopsy is usually conducted transrectal, ultrasonography guided. Since the area is not sterile, infection can be induced during the procedure.

Prophylaxis antibiotic against gram-negative bacteria decreased significantly the amount of infections. Quinolones are considered preferred treatment but there is already an increase in resistance rates. TMP-SMX can not be used empirically due to a high percent of resistant uropathogens. One of the options is aminoglycosides, especially gentamicin. Advantages: very low resistance rate in the community, high concentration is urinary tract, slow clearance, no resistance developed under treatment, chip and with very few side effects.


Condition Intervention Phase
Infection
Drug: ofloxacin
Drug: gentamicin
Phase IV

Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Ofloxacin vs. Gentamicin as Prophylaxis Prior Transrectal Biopsy of Prostate

Resource links provided by NLM:


Further study details as provided by HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • no infection [ Time Frame: 48 hours ]

Secondary Outcome Measures:
  • no infection [ Time Frame: 7 days ]

Estimated Enrollment: 160
Study Start Date: June 2007
Estimated Study Completion Date: March 2008
Detailed Description:

Prostate biopsy is usually conducted as an ambulatory transrectal needle aspiration, ultrasonography guided. The area is not sterile, with high concentration of gram-negative and anaerobic pathogens, infection can be induced during the procedure to the urinary tract, and even cause bacteremia.

Prior studies concluded that prophylaxis antibiotic against gram-negative bacteria decreased significantly the amount of infections and hence it is accepted to give prophylaxis antibiotics which will cover especially gram-negative bacteria. Other studies show decrease in infections percent in patients that received prophylaxis opposed to those who did not, from 5-30% to less than 1%. Yet, there was no significant difference between those who received one dose and those who were treated for 3-5 days. Quinolones are considered preferred treatment since they can be given orally, but there is already an increase in resistance rates. TMP-SMX can not be used empirically due to a high percent of resistant uropathogens. One of the options is aminoglycosides, especially gentamicin. Advantages: very low resistance rate in the community, high concentration is urinary tract, slow clearance, no resistance developed under treatment, chip and with very few side effects.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients going under transrectal biopsy of prostate with sterile urine culture.

Exclusion Criteria:

  • Urine culture not sterile
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00480376

Contacts
Contact: Genady Zelichenko, M.D. 972-4-6494000 ext 306 genady_ze@clalit.org.il

Locations
Israel
Urology outpatient clinic, HaEmek MC
Afula, Israel, 18101
Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Principal Investigator: Genady Zelychenko, MD Ha'Emek Medical Center, Afula, Israel
  More Information

No publications provided

Study ID Numbers: 230105
Study First Received: May 29, 2007
Last Updated: May 29, 2007
ClinicalTrials.gov Identifier: NCT00480376     History of Changes
Health Authority: Israel: Ethics Commission

Keywords provided by HaEmek Medical Center, Israel:
transrectal biopsy
prostate
prophylaxis antibiotic

Additional relevant MeSH terms:
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Ofloxacin
Enzyme Inhibitors
Anti-Infective Agents, Urinary
Infection
Renal Agents
Pharmacologic Actions
Anti-Bacterial Agents
Protein Synthesis Inhibitors
Therapeutic Uses
Gentamicins
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on February 08, 2010